Arginase II's Role in L-Arginine Depletion and Tumor Growth in Kidney Cancer
Author Information
Author(s): Tate David J Jr, Vonderhaar Derek J, Caldas Yupanqui A, Metoyer Toye, Patterson John R IV, Aviles Diego H, Zea Arnold H
Primary Institution: Stanley S. Scott Cancer Center, LSUHSC, New Orleans, USA
Hypothesis
Arginase II in renal cell carcinoma (RCC) cell lines depletes L-arginine and affects cell growth.
Conclusion
Arginase II from RCC cell lines depletes L-arginine, which decreases T-cell function and may be targeted for therapeutic benefits.
Supporting Evidence
- mRCC cell lines express only arginase II and deplete L-arginine from the medium.
- Cell growth was independent of arginase activity levels.
- nor-NOHA significantly reduced arginase II activity and suppressed cell growth in high arginase activity cells.
- L-arginine depletion decreased CD3ΞΆ expression, affecting T-cell function.
Takeaway
This study shows that a protein called arginase II in kidney cancer cells uses up an important nutrient called L-arginine, which can make it harder for the immune system to work.
Methodology
Murine renal cell carcinoma cell lines were tested for arginase activity and L-arginine levels using HPLC and proliferation assays with arginase inhibitors.
Potential Biases
Potential bias in the interpretation of results due to the use of specific cell lines.
Limitations
The study is limited to murine cell lines and may not fully represent human RCC behavior.
Participant Demographics
Murine renal cell carcinoma cell lines were used, with no human participants.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website